Stock Events

Gilead Sciences 

€82.36
+€0.88+1.08% Friday 16:29

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
3.38%
Dividend
2.78

Upcoming

Dividends

3.38%Dividend Yield
10Y Growth
N/A
5Y Growth
4.56%
3Y Growth
5.23%
1Y Growth
1.15%

Earnings

4FebExpected
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q2 2024
Next
1.47
1.7
1.92
2.14
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1GILD.MI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie competes directly with Gilead in the areas of hepatitis C treatments and is also a major player in immunology and oncology.
Merck
MRK
Mkt Cap300.25B
Merck & Co. offers competitive products in the antiviral space, including treatments for HIV and hepatitis C, directly challenging Gilead's core market.
Pfizer
PFE
Mkt Cap164.39B
Pfizer competes across several therapeutic areas including oncology, immunology, and antiviral drugs, overlapping with Gilead's product portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb is a key competitor in the oncology and immunology sectors, areas where Gilead Sciences is actively expanding its presence.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the HIV and hepatitis C markets, among others, where Gilead has significant interests.
AMGEN
AMGN
Mkt Cap179.38B
Amgen competes with Gilead in the biopharmaceutical space, particularly in the areas of oncology and inflammatory diseases.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline, through its ViiV Healthcare joint venture, is a strong competitor in the HIV treatment market, directly challenging Gilead's leadership.
Novartis
NVS
Mkt Cap244.75B
Novartis competes with Gilead in several areas including oncology and gene therapy, with both companies investing heavily in research and development.
Roche
RHHBY
Mkt Cap272.83B
Roche, through its Genentech unit, competes in the oncology and antiviral markets, areas where Gilead has key products.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca competes with Gilead in the oncology sector, with both companies developing treatments for various cancers.

About

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Show more...
CEO
Mr. Daniel P. O'Day
Employees
14400
Country
United States
ISIN
US3755581036

Listings